azacitidine has been researched along with Anemia, Refractory in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanamoto, H; Ishikawa, J; Kawata, S; Maeda, Y; Matsuda, M; Matsumura, I; Morita, Y; Shibayama, H; Tsubaki, K; Urase, F; Yamaguchi, T | 1 |
| Kotoula, V; Papaioannou, M; Sapalidis, K | 1 |
| Backstrom, J; Beach, CL; Fenaux, P; Gore, SD; Hellström-Lindberg, E; List, A; Mufti, GJ; Santini, V; Seymour, JF; Silverman, LR | 1 |
| Kim, J; Kim, YR; Lee, KA | 1 |
| Barrales-Benítez, O; Flores, M; López-Karpovitch, X; Piedras, J | 1 |
| Huijgens, PC; Krulder, JW; Neve, P; Wijermans, PW | 1 |
| Andre, M; Bosly, A; Ferrant, A; Kunzmann, R; Lübbert, M; Ravoet, C; Verhoef, G; Wijermans, P | 1 |
2 trial(s) available for azacitidine and Anemia, Refractory
| Article | Year |
|---|---|
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Drug Administration Schedule; Feasibility Studies; Febrile Neutropenia; Female; Humans; Japan; Male; Middle Aged; Prospective Studies; Thrombocytopenia; Treatment Outcome | 2018 |
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2010 |
5 other study(ies) available for azacitidine and Anemia, Refractory
| Article | Year |
|---|---|
Alleviation of myelodysplastic syndrome-associated skin rush after treatment with decitabine.
Topics: Aged; Anemia, Refractory; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Y; Decitabine; Exanthema; Humans; Male | 2008 |
Refractory anemia with ring sideroblasts associated with marked thrombocytosis harboring cytogenetic abnormality dup(2)(p15p22) treated with decitabine.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Duplication; Chromosomes, Human, Pair 2; Decitabine; Humans; Male; Middle Aged; Thrombocytosis | 2012 |
Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin m, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia.
Topics: Adult; Aged; Anemia, Refractory; Antimetabolites; Azacitidine; Cells, Cultured; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Female; Growth Inhibitors; Humans; Interleukin-11; Interleukin-6; Leukemia Inhibitory Factor; Leukocytes, Mononuclear; Lymphokines; Male; Middle Aged; Oncostatin M; Peptides; Phytohemagglutinins | 2002 |
Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia | 1997 |
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosome Disorders; Decitabine; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Survival Rate | 2001 |